Related Experiment Video

Updated: Nov 2, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.1K

SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis

R Piñar Morales1, M A Ramírez Rivas2, F J Barrero Hernández3

  • 1Servicio de Neurología, Hospital Universitario Clínico San Cecilio, Granada, Spain.

Neurologia
|June 9, 2021
PubMed
Abstract

Insights

COVID-19 incidence was slightly higher in multiple sclerosis (MS) patients, but disease-modifying therapies (DMT) did not affect COVID-19 outcomes. Unfavorable prognosis was linked to older age and higher disability scores.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • The impact of SARS-CoV-2 on multiple sclerosis (MS) patients and the role of disease-modifying therapies (DMTs) in COVID-19 outcomes remain unclear.
  • Current evidence suggests MS patients may not face a higher risk or more severe COVID-19 progression.

Purpose of the Study:

  • To investigate the clinical course and outcomes of COVID-19 in patients with multiple sclerosis.
  • To assess the influence of disease-modifying therapies (DMTs) on COVID-19 severity in MS patients.

Main Methods:

  • A descriptive study was conducted on MS patients diagnosed with SARS-CoV-2 via PCR.
  • Demographic, clinical, laboratory, and treatment data were analyzed, including antibody presence against SARS-CoV-2.

Main Results:

  • Relapsing-remitting MS (RRMS) was the most common form. Unfavorable prognosis occurred in 10.2% of patients, associated with older age and higher Expanded Disability Status Scale (EDSS) scores.
  • Seroprevalence of SARS-CoV-2 antibodies was 83.3%, not associated with DMTs or lymphocytopenia.
  • COVID-19 incidence was slightly elevated compared to the general population.

Conclusions:

  • Older age and higher EDSS scores were associated with unfavorable COVID-19 prognosis in MS patients.
  • DMTs and lymphocytopenia did not significantly influence the clinical course of COVID-19 in this cohort.
  • Antibody seroprevalence was comparable to the general population; specific DMT effects on antibody development could not be determined.
Keywords:
COVID-19Covid-19Disease-modifying therapyEsclerosis múltipleLinfopeniaLymphocytopaeniaMultiple sclerosisSARS-CoV-2SeroprevalenceSeroprevalenciaTratamiento modificador de la enfermedad

More Related Videos

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.9K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.1K